AstraZeneca and Merck Establish Strategic Oncology Partnership, page-8

The PARP inhibitors, have been exciting for sure, they have their own toxicities though and combining them with highly toxic PDL1 inhibitors will have a new set of toxicity. Only time will tell. The reduction in toxicity so far seen when combining Cavatak with the checkpoint inhibitors continues to be "unprecedented". There is "0" chance, in my opinion.... that a PARP inhibitor will reduce overall toxicity when combined with checkpoint inhibitors. Sit tight on results from the combo trials. IMO again, they have the data already that points to a successful combo program with the checkpoint inhibitors.

Management needs to earn their high salaries and get a few milestones completed that other biotech's in the cancer field get done.

Why haven't they applied for and received "breakthrough therapy" designation at FDA.
This is the kind of milestone that I have seen generate buying of the shares of other small biotechs, and the kind of stuff you get done while waiting for results.
If a drug is designated as breakthrough therapy, FDA will expedite the development and review of such drug. All requests for breakthrough therapy designation will be reviewed within 60 days of receipt, and FDA will either grant or deny the request.
Management and BOD continue to "underperform".